329 related articles for article (PubMed ID: 27091662)
1. The role of glycans in the development and progression of prostate cancer.
Munkley J; Mills IG; Elliott DJ
Nat Rev Urol; 2016 Jun; 13(6):324-33. PubMed ID: 27091662
[TBL] [Abstract][Full Text] [Related]
2. Glycosylation is a global target for androgen control in prostate cancer cells.
Munkley J
Endocr Relat Cancer; 2017 Mar; 24(3):R49-R64. PubMed ID: 28159857
[TBL] [Abstract][Full Text] [Related]
3. Glycans as Biomarkers in Prostate Cancer.
Scott E; Munkley J
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30893936
[TBL] [Abstract][Full Text] [Related]
4. The Complexity and Dynamics of the Tissue Glycoproteome Associated With Prostate Cancer Progression.
Kawahara R; Recuero S; Srougi M; Leite KRM; Thaysen-Andersen M; Palmisano G
Mol Cell Proteomics; 2021; 20():100026. PubMed ID: 33127837
[TBL] [Abstract][Full Text] [Related]
5. Targeting aberrant sialylation and fucosylation in prostate cancer cells using potent metabolic inhibitors.
Orozco-Moreno M; Visser EA; Hodgson K; Hipgrave Ederveen AL; Bastian K; Goode EA; Öztürk Ö; Pijnenborg JFA; Eerden N; Moons SJ; Rossing E; Wang N; de Haan N; Büll C; Boltje TJ; Munkley J
Glycobiology; 2023 Dec; 33(12):1155-1171. PubMed ID: 37847613
[TBL] [Abstract][Full Text] [Related]
6. Glycosylation: Rising Potential for Prostate Cancer Evaluation.
Kałuża A; Szczykutowicz J; Ferens-Sieczkowska M
Cancers (Basel); 2021 Jul; 13(15):. PubMed ID: 34359624
[TBL] [Abstract][Full Text] [Related]
7. Glycosylation in Indolent, Significant and Aggressive Prostate Cancer by Automated High-Throughput
Gilgunn S; Murphy K; Stöckmann H; Conroy PJ; Murphy TB; Watson RW; O'Kennedy RJ; Rudd PM; Saldova R
Int J Mol Sci; 2020 Dec; 21(23):. PubMed ID: 33287410
[TBL] [Abstract][Full Text] [Related]
8. Increased bisecting N-acetylglucosamine and decreased branched chain glycans of N-linked glycoproteins in expressed prostatic secretions associated with prostate cancer progression.
Nyalwidhe JO; Betesh LR; Powers TW; Jones EE; White KY; Burch TC; Brooks J; Watson MT; Lance RS; Troyer DA; Semmes OJ; Mehta A; Drake RR
Proteomics Clin Appl; 2013 Oct; 7(9-10):677-89. PubMed ID: 23775902
[TBL] [Abstract][Full Text] [Related]
9. Glycosylation products in prostate diseases.
Dos Santos Silva PM; Albuquerque PBS; de Oliveira WF; Coelho LCBB; Dos Santos Correia MT
Clin Chim Acta; 2019 Nov; 498():52-61. PubMed ID: 31400314
[TBL] [Abstract][Full Text] [Related]
10. Integrated Proteomic and Glycoproteomic Analyses of Prostate Cancer Cells Reveal Glycoprotein Alteration in Protein Abundance and Glycosylation.
Shah P; Wang X; Yang W; Toghi Eshghi S; Sun S; Hoti N; Chen L; Yang S; Pasay J; Rubin A; Zhang H
Mol Cell Proteomics; 2015 Oct; 14(10):2753-63. PubMed ID: 26256267
[TBL] [Abstract][Full Text] [Related]
11. The role of GCNT1 mediated O-glycosylation in aggressive prostate cancer.
Hodgson K; Orozco-Moreno M; Scott E; Garnham R; Livermore K; Thomas H; Zhou Y; He J; Bermudez A; Garcia Marques FJ; Bastian K; Hysenaj G; Archer Goode E; Heer R; Pitteri S; Wang N; Elliott DJ; Munkley J
Sci Rep; 2023 Oct; 13(1):17031. PubMed ID: 37813880
[TBL] [Abstract][Full Text] [Related]
12.
Conroy LR; Stanback AE; Young LEA; Clarke HA; Austin GL; Liu J; Allison DB; Sun RC
Mol Cancer Res; 2021 Oct; 19(10):1727-1738. PubMed ID: 34131069
[TBL] [Abstract][Full Text] [Related]
13. Core fucosylation and alpha2-3 sialylation in serum N-glycome is significantly increased in prostate cancer comparing to benign prostate hyperplasia.
Saldova R; Fan Y; Fitzpatrick JM; Watson RW; Rudd PM
Glycobiology; 2011 Feb; 21(2):195-205. PubMed ID: 20861084
[TBL] [Abstract][Full Text] [Related]
14. Glycosylation status of haptoglobin in sera of patients with prostate cancer vs. benign prostate disease or normal subjects.
Fujimura T; Shinohara Y; Tissot B; Pang PC; Kurogochi M; Saito S; Arai Y; Sadilek M; Murayama K; Dell A; Nishimura S; Hakomori SI
Int J Cancer; 2008 Jan; 122(1):39-49. PubMed ID: 17803183
[TBL] [Abstract][Full Text] [Related]
15. Glycosylation status of serum immunoglobulin G in patients with prostate diseases.
Kazuno S; Furukawa J; Shinohara Y; Murayama K; Fujime M; Ueno T; Fujimura T
Cancer Med; 2016 Jun; 5(6):1137-46. PubMed ID: 26880719
[TBL] [Abstract][Full Text] [Related]
16. Glycosylation Changes in Prostate Cancer Progression.
Butler W; Huang J
Front Oncol; 2021; 11():809170. PubMed ID: 35004332
[TBL] [Abstract][Full Text] [Related]
17. Shifted Golgi targeting of glycosyltransferases and α-mannosidase IA from giantin to GM130-GRASP65 results in formation of high mannose N-glycans in aggressive prostate cancer cells.
Bhat G; Hothpet VR; Lin MF; Cheng PW
Biochim Biophys Acta Gen Subj; 2017 Nov; 1861(11 Pt A):2891-2901. PubMed ID: 28782625
[TBL] [Abstract][Full Text] [Related]
18. Alterations in protein expression and site-specific N-glycosylation of prostate cancer tissues.
Sugár S; Tóth G; Bugyi F; Vékey K; Karászi K; Drahos L; Turiák L
Sci Rep; 2021 Aug; 11(1):15886. PubMed ID: 34354152
[TBL] [Abstract][Full Text] [Related]
19. Lectin Affinity Chromatography for the Discovery of Novel Cancer Glycobiomarkers: A Case Study with PSA Glycoforms and Prostate Cancer.
Llop E; Peracaula R
Methods Mol Biol; 2022; 2370():301-313. PubMed ID: 34611876
[TBL] [Abstract][Full Text] [Related]
20. Comprehensive N-glycome profiling of cultured human epithelial breast cells identifies unique secretome N-glycosylation signatures enabling tumorigenic subtype classification.
Lee LY; Thaysen-Andersen M; Baker MS; Packer NH; Hancock WS; Fanayan S
J Proteome Res; 2014 Nov; 13(11):4783-95. PubMed ID: 25210975
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
